Abstract:Introduction: Human myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular system. Experimental autoimmune myasthenia gravis (EAMG) is a well-established animal model for MG that can be induced by active immunization with the Torpedo californica-derived acetylcholine receptor (AChR). Due to the expensive cost of purifying AChR from Torpedo californica, the development of an easier and more economical way of inducing EAMG remains critically needed. Material and methods: Full-length cDNA of the human skeletal muscle AChR α1 subunit was obtained from TE671 cells. The DNA fragment encoding the extracellular domain (ECD) was then amplified by polymerase chain reaction (PCR) and inserted into pET-16b. The reconstructed plasmid was transformed into the host strain BL21(DE3)pLysS, which was derived from Escherichia coli. Isopropyl-β-D-thiogalactopyranoside (IPTG) was used to induce the expression of the N-terminal ECD. The produced protein was purified with immobilized Ni(2+) affinity chromatography and refolded by dialysis. Results: The recombinant protein was efficiently refolded to soluble active protein, which was verified by ELISA. After immunization with the recombinant ECD, all rats acquired clinical signs of EAMG. The titer of AChR antibodies in the serum was significantly higher in the EAMG group than in the control group, indicating successful induction of EAMG. Conclusions: We describe an improved procedure for refolding recombinant ECD of human muscle AChR. This improvement allows for the generation of large quantities of correctly folded recombinant ECD of human muscle AChR, which provides for an easier and more economical way of inducing the animal model of MG.

Improved methodology to obtain large quantities of correctly folded recombinant N-terminal extracellular domain of the human muscle acetylcholine receptor for inducing experimental autoimmune myasthenia gravis in rats

Development of an improved animal model of experimental autoimmune myositis.

Establishment of a Mouse Model of Experimental Autoimmune Myasthenia Gravis

Establishment of Animal Models of Experimental Autoimmune Myositis

Artificial Construction of Human Pathogenic Autoantibody in Myasthenia Gravis

A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis

Potential Roles of Recombinant Acetylcholine Receptor Α Subunit 1–211 in Immunoadsorbent and DNA Immunization

Establishment of the animal model of experimental autoimmune myositis

Expression of a highly antigenic and native-like folded extracellular domain of the human α1 subunit of muscle nicotinic acetylcholine receptor, suitable for use in antigen specific therapies for Myasthenia Gravis

Institution of Model of Myasthenia Gravis in Transgenic Mice

Suppression of Experimental Autoimmune Myasthenia Gravis by Nasal Administration of Acetylcholine Receptor

Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci

Construction of a myasthenia gravis model by immunizing mice with gene vaccine pcDNA-AChR_(α211)

Induce Experimental Autoimmune Myasthenia Gravis on Rats by Passive Transfer Acetylcholine Receptor Monoclonal Antibody

Expression and Refolding of the Extracellular Domain of the Human Acetylcholine Receptor Al Subunit

Amelioration of Experimental Autoimmune Myasthenia Gravis Rats Using 4-Mercaptoethylpyridine-based Adsorbent

AEB-071 Ameliorates Muscle Weakness by Altering Helper T Lymphocytes in an Experimental Autoimmune Myasthenia Gravis Rat Model

Pathogenesis of Myasthenia Gravis in Transgenic Mouse Induced with Torpedo Acetylcholine Receptor

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

Modified radioimmunoassay versus ELISA to quantify anti-acetylcholine receptor antibodies in a mouse model of myasthenia gravis

Selective Recognition and Elimination of Nicotinic Acetylcholine Receptor-Reactive B Cells by A Recombinant Fusion Protein Achr-Fc in Myasthenia Gravis in Vitro